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Abstract Guidelines change every few years regarding
the prophylactic use of Bacille Calmette-Guérin (BCG)
against non-muscle invasive bladder cancer. We per-
formed a retrospective comparison to clarify the differ-
ences in BCG efficacy, based on time period, between
Japan and Western countries . Published literature on
18 Japanese and 28 Western patient studies were com-
pared to evaluate differences in BCG efficacy. Addi-
tionally, Internet searches were performed to obtain
comparative Japanese and Western data. BCG efficacy
in Japanese literature tended to show decreasing non-
recurrence rates by time period. Non-recurrence rates in
Western countries increased each year. This discrepancy
may stem from a number of factors, including changes
in accepted BCG indications, the introduction of
restaging transurethral resection (re-TUR), the concept
of BCG maintenance, and the evolution of histopatho-
logical diagnostic criteria.
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Introduction
For the past two decades, intravesical Bacille Calmette-Guérin
(BCG) instillation therapy has been considered the worldwide
gold standard for the treatment of non-muscle invasive bladder
cancer (NMIBC) [1–3]. Initially, there were no generally accept-
ed guidelines or risk classifications. After trial and error, the first
guidelines for BCG indication were published in 1999 by the
American Urological Association (AUA) [1]. Subsequently, two
major sets of guidelines were published by the European Asso-
ciation of Urology (EAU) [2] and the National Comprehensive





guidelines.cfm?sub=bc). Additionally, several guidelines have
been developed worldwide. In particular, guidelines for the
prophylactic use of BCG against NMIBC have been revised
due to modifications in the pathological diagnostic
classifications, the introduction and consensus regarding
restaging transurethral resection (re-TUR) procedures [3, 4,
5••], and other technical or mechanical improvements.
However, there have been no publications concerning the
variations in outcome due to changes in the guidelines for
BCG application. Therefore, we conducted a retrospective com-
parison to clarify differences in BCG efficacy, according to time
period, between patients in Japan and Western countries.
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Methods
Data Selection and Collection
Japanese Literature Records
A total of 18 papers (22 treatment arms) were chosen according
to the criteria described below [6–23]. The literature searches
were conducted to include reports published between January
1985 and July 2011. All literature was identified via PubMed
database searches, which were limited to human subjects and
contained the MeSH term “bladder neoplasms” with additional
search terms “BCG” or “bacillus Calmette-Guérin” and “Japan.”
Additional searches were conducted on the Japanese electronic
database JAPIC (Japan Pharmaceutical Information Center). All
identified studies were conductedwithin Japan. The beginning of
the studies was clearly described, and the study registration
periods occurred within five years. The enrolled cases were
limited to those of intermediate to high risk, and the studies did
not focus on particular patient categories such as those with
carcinoma in situ (CIS) or T1G3 disease. Combinations with
other agents that might be influenced by the effects of BCGwere
excluded, and other anticancer agents were not used.
Western Literature Records
The literature searches included reports published between Jan-
uary 1985 andMay 2012. The searches were limited to reports of
human subjects that were published in the English language and
included the MeSH term “bladder neoplasms” with additional
search terms “BCG” or “bacillus Calmette-Guérin.” The initial
database search returned a collection of 1,833 reports, which
were subsequently narrowed to 228 reports. From these reports,
28 reports (38 treatment arms) were chosen [24–50, 51••], ac-
cording to the same conditions that were used to select Japanese
patient literatures, which are described below. All studies were
performed outside of Japan. The beginning of the studies was
clearly described, and the registration periods occurred within
5 years. The enrolled cases were limited to those of intermediate
to high risk, and the studies did not focus on particular patient
categories such as those with CIS or T1G3 disease. Combina-
tions with other agents that might be influenced by the effects of
BCG were excluded, and other anticancer agents were not used.
A non-recurrence rate graph based on the above-described
data was plotted for each time period at the beginning of the
study. In studies that contained two or more BCG treatment
arms, every arm was plotted.
Statistical Analyses
Simple linear regression analysis was used to determine the
correlation coefficient between the period of BCG treatment
and clinical variables. All statistical analyses were performed
using Microsoft Office Excel 2007.
Results
Most of the Japanese literature reports were published before
2000 [6–17]. Recent reports focused mainly on particular cases
such as T1G3 cases or on specific institutional outcomes. BCG
studies greater than 10 years in length were reported with
increasing frequency after 2000; these reports were unsuitable
for our study. Surprisingly, in the 1980s and early 1990s,
patients with Ta, G1, or G2 cases were often overlooked [6–14].
This trend changed after a survey by the Japanese Urologi-
cal Association in 1999–2001 [52]. The patient backgrounds
that were considered widened dramatically, and BCG was
used to treat many T1 and/or G3 cases. During the survey
period, BCG was normally used for high-risk cases.
Figure 1 shows the initial treatment year of the BCG
intravesical therapy studies and the 3-year non-recurrence
rates. Although the 3-year non-recurrence rate appeared to
have decreased gradually in recent years, there was no statis-
tical correlation between the starting year and the 3-year
non-recurrence rate.
The correlation between treatment time period and patient age
was examined. A trend toward increased patient age was seen in
recent years, but no statistical correlation was observed (Fig. 2).
A summary comparison of literature data between the late-
1990s and earlier periods demonstrates that BCG is widely used
in high-risk patients such as T1G3 cases. Furthermore, it is
possible that patient age has an effect on therapeutic outcome.
On the other hand, our analyses of the data from Western
countries showed a trend toward increased non-recurrence
rates (Fig. 3).
With regard to patient background, the percentage of high-
risk patients has increased both in Japan and in Western
countries (Europe and the United States).
The reported median age of patients in Japanese literature
increased by approximately 2 years over a period of greater
than 20 years; however, the median age of patients in
Western countries was almost unchanged over the time
periods studied (Fig. 4).
Discussion
The results of our study indicated a trend toward decreasing
non-recurrence rates in Japanese patients after the year 2000,
which may be related to differences in study background
characteristics such as greater average numbers of tumors
per case or increased numbers of low-dose cases. On the other
hand, the prophylactic effects of BCG appeared to increase
annually in Western countries. We believe that this is the first
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literature review of BCG intravesical instillation therapy strat-
ified by age.
Clearly, there are a number of factors that may
account for the trend in the Japanese cases. In the
1980s, BCG was introduced as a promising treatment
option for recurrent NMIBC (initially referred to as
superficial bladder cancer), which led to the global
use of BCG. However, many severe adverse effects
were reported, including anaphylactic shock, arthritis,
Reiter’s syndrome, general tuberculosis infection, and
contracted bladder. In response to this, applied doses
were reduced [49, 53]. However, most dose-dependent
comparisons did not show dose-related variations in
efficacy [54, 55]. Additionally, the BCG indication criteria
were changed so that more stringent patient selection guide-
lines were provided annually in the United States and other





sub=bc). The applied criteria were also changed in Japan
(bladder cancer practice guideline: Japanese Urological
Association, 2009).
The Spanish Urological Club for Oncological Treatment
reported on a scoring system for factors that affected progno-
sis in patients who had received intravesical BCG therapy
[56]. Age and gender were newly discovered prognostic fac-
tors in this study, in contrast to those reported by the European
Organisation for Research and Treatment of Cancer, which
accounted for almost no BCG cases. However, T-
classification and tumor size were not found to be prognostic
factors. These factors may have influenced BCG therapy
outcomes in Western countries to some extent.
Although changes in histopathological bladder cancer
grading and staging criteria could have an impact, the
distinction between high-malignant potential and non-

















Fig. 1 Analysis of the correlation
between the year of BCG
treatment initiation and the 3-year
non-recurrent survival rate











Fig. 2 Median age distribution
according to the 18 Japanese
patient references
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more emphasis. Consequently, the name “superficial
bladder cancer” was changed to NMIBC, and in Japan,
pathological classifications were modified in the 1990s
from T1a and T1b to T1 only.
Patient age is another potential factor in Japanese
cases. In fact, a trend toward increased patient age at
BCG application was observed in the 18 Japanese pa-
pers reviewed, as shown in Fig. 2. Several reports,
including our own, have described lower efficacy rates
for BCG therapy in elderly patients [57–59, 60••]. In
Japanese literature, the median patient age increased by
approximately 2 years over a 20-year period. Almost no
change in patient age was observed in the Western
countries (Fig. 4). The relationship between patient age
and BCG efficacy is still not clearly understood.
Number of intravesical BCG instillations is another possi-
ble factor. Maintenance therapy has been established in Eu-
rope and the United States, and intravesical instillation time is
therefore greater than in Japanese cases.
Initially, large numbers of BCG administrations were re-
ported in the Japanese cases, but more recently, the number of
administrations was reduced to 6 or 8. BCG for intravesical,
with a treatment schedule of 8 administrations, was first
approved in Japan in 1996. Maintenance administrations were
approved in 2010.
We found no direct correlation between patient background
and therapeutic strategy transitions. Trial-and-error variability,
periods in which targets and methods were more firmly
established, and periods of increased maintenance therapy
were found to exist in all time periods
Conclusions
The results of this study revealed an annual trend toward
decreasing non-recurrence rates in Japanese studies. However,
these results conflicted with those from studies in Western
countries. This discrepancy may stem from a number of
factors, including changes in accepted BCG indications, the
introduction of re-TUR, the concept of BCG maintenance,

















Fig. 3 Analysis of the correlation
between the year of BCG
treatment initiation and the 3-year
non-recurrence survival rate
according to the 28 literature











Fig. 4 Median age distribution
according to the 28 references of
patients in Western countries
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